Virax Biolabs Company Insiders
| VRAX Stock | USD 1.69 0.23 11.98% |
Virax Biolabs employs about 17 people. The company is managed by 10 executives with a total tenure of roughly 40 years, averaging almost 4.0 years of service per executive, having 1.7 employees per reported executive. Break down of Virax Biolabs' management performance can provide insight into the company performance.
Virax |
Virax Biolabs Management Team Effectiveness
The company has return on total asset (ROA) of (0.499) % which means that it has lost $0.499 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.9598) %, meaning that it created substantial loss on money invested by shareholders. Virax Biolabs' management efficiency ratios could be used to measure how well Virax Biolabs manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -1.17 in 2025. Return On Capital Employed is likely to rise to -1.34 in 2025. At this time, Virax Biolabs' Net Tangible Assets are fairly stable compared to the past year. Non Current Assets Total is likely to rise to about 1.3 M in 2025, whereas Total Assets are likely to drop slightly above 3.4 M in 2025.Common Stock Shares Outstanding is likely to drop to about 1.4 M in 2025. Net Loss is likely to rise to about (4.7 M) in 2025
Virax Biolabs Workforce Comparison
Virax Biolabs Group is rated third in number of employees category among its peers. The total workforce of Health Care industry is at this time estimated at about 147. Virax Biolabs retains roughly 17.0 in number of employees claiming about 12% of equities under Health Care industry.
Virax Biolabs Group Benchmark Summation
Operator |
The output start index for this execution was zero with a total number of output elements of sixty-one. Virax Biolabs Group Price Series Summation is a cross summation of Virax Biolabs price series and its benchmark/peer.
Virax Biolabs Notable Stakeholders
A Virax Biolabs stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Virax Biolabs often face trade-offs trying to please all of them. Virax Biolabs' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Virax Biolabs' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Mark Ternouth | Chief Director | Profile | |
| Tomasz George | Chief Officer | Profile | |
| Joel Yeung | Accounting Manager | Profile | |
| Nigel MSc | Chief Officer | Profile | |
| Cameron Shaw | COO Director | Profile | |
| James Wang | Head Sourcing | Profile | |
| James Foster | Chairman CEO | Profile | |
| Jason Davis | Chief Officer | Profile | |
| Lily Fu | Head Chain | Profile | |
| Clement Monteil | Head Development | Profile |
About Virax Biolabs Management Performance
The success or failure of an entity such as Virax Biolabs Group often depends on how effective the management is. Virax Biolabs management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Virax management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Virax management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (1.12) | (1.17) | |
| Return On Capital Employed | (1.41) | (1.34) | |
| Return On Assets | (1.11) | (1.16) | |
| Return On Equity | (1.44) | (1.37) |
Please note, the imprecision that can be found in Virax Biolabs' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Virax Biolabs Group. Check Virax Biolabs' Beneish M Score to see the likelihood of Virax Biolabs' management manipulating its earnings.
Virax Biolabs Workforce Analysis
Traditionally, organizations such as Virax Biolabs use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Virax Biolabs within its industry.Virax Biolabs Manpower Efficiency
Return on Virax Biolabs Manpower
| Revenue Per Employee | 9.2K | |
| Revenue Per Executive | 15.6K | |
| Net Loss Per Employee | 396.4K | |
| Net Loss Per Executive | 673.9K | |
| Working Capital Per Employee | 247.7K | |
| Working Capital Per Executive | 421.1K |
Additional Tools for Virax Stock Analysis
When running Virax Biolabs' price analysis, check to measure Virax Biolabs' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Virax Biolabs is operating at the current time. Most of Virax Biolabs' value examination focuses on studying past and present price action to predict the probability of Virax Biolabs' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Virax Biolabs' price. Additionally, you may evaluate how the addition of Virax Biolabs to your portfolios can decrease your overall portfolio volatility.